With $260m Settlement From Sanofi, Lexicon Looks For New Zynquista Partner

 
• By Joseph Haas

Sanofi terminated its alliance for the SGLT1/2 inhibitor Zynquista, giving Lexicon full control of development in type 1 and type 2 diabetes, but it is seeking a new partner ideally with a European footprint.

Businessman-puzzle
The Lexicon/Sanofi split is finalized two months after the French pharma said it wanted out

More from Deals

More from Business